Sign in

CIK 0001400118 · <br>Emerging growth company

Sagimet Biosciences Inc.

Sign in to watch
Ticker
SGMT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
205991472
Phone
(650) 561-8600
Business address
950 TOWER LANE, STE 1500, FOSTER CITY, CA, 94404
Former names
3-V Biosciences, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2023-07-18 SEIDENBERG BETH C Director Returned to the company −38,763 0
2023-07-18 SEIDENBERG BETH C Director Grant or award +38,763 38,763
2023-07-18 SEIDENBERG BETH C Director Conversion +1,860,712 1,899,475
2023-07-18 SEIDENBERG BETH C Director Conversion +84,768 84,768
2023-07-18 SEIDENBERG BETH C Director Purchase +46,875 $16.00 $750K 46,875
2023-07-18 SEIDENBERG BETH C Director Conversion · Series A Preferred Stock −539,006 0
2023-07-18 SEIDENBERG BETH C Director Conversion · Series B Preferred Stock −493,370 0
2023-07-18 SEIDENBERG BETH C Director Conversion · Series B-1 Preferred Stock −8,596,590 0
2023-07-18 SEIDENBERG BETH C Director Conversion · Series C Preferred Stock −8,596,589 0
2023-07-18 SEIDENBERG BETH C Director Conversion · Series D Preferred Stock −6,103,580 0
2023-07-18 SEIDENBERG BETH C Director Conversion · Series E Preferred Stock −6,737,254 0
2023-07-18 SEIDENBERG BETH C Director Conversion · Series E Preferred Stock −103,127,234 0
2023-07-18 SEIDENBERG BETH C Director Conversion · Series F Preferred Stock −20,430,107 0
2023-07-18 SEIDENBERG BETH C Director Returned to the company · Stock Option (Right to Buy) −23,216 0
2023-07-18 SEIDENBERG BETH C Director Grant or award · Stock Option (Right to Buy) +23,216 23,216
2023-07-18 Wu Jinzi Jason Director Conversion +1,654,701 1,654,701
2023-07-18 Wu Jinzi Jason Director Conversion · Series E Preferred Stock −108,471,634 0
2023-07-18 Wu Jinzi Jason Director Conversion · Series F Preferred Stock −23,041,474 0
2023-07-18 Wu Jinzi Jason Director Returned to the company · Stock Option (Right to Buy) −23,216 0
2023-07-18 Wu Jinzi Jason Director Grant or award · Stock Option (Right to Buy) +23,216 23,216

Page 7 of 10 · 194 trades